小智港股覆盤 | 12月23日
今日，港股三大指數集體下跌。截止收盤，恆生指數跌0.44%，報19593點。國企指數跌1.09%，報6642點。恆生科技指數大跌2.05%，報4124點。市場約698只個股上漲，881只個股下跌。成交額突破799.59億港幣，和昨天同期相比下跌21.2%。南下資金淨流入6.8億港幣。
盤面上，生物科技板塊集體拉昇。和鉑醫藥-B漲超36%；諾誠健華-B漲超14%；雲頂新耀-B、百濟神州、三葉草生物-B等多股漲超6%。和鉑醫藥-B升15% 整體業務劃分兩大板塊 HBM4003最新臨牀研究結果發佈；諾誠健華-BA股漲超9% H股漲近7%，BTK抑制劑聯合療法獲批II期臨牀試驗；雲頂新耀-B升10% Etrasimod美、歐上市許可申請獲受理 mRNA新冠疫苗擬於海外進行III期臨牀；百濟神州漲6%，摩根大通好倉增近6個百分點，澤布替尼發佈最新優效性結果；高盛上調三葉草生物-B目標價至3.37港元，微調盈測以反映配股事項。
綜合電信板塊大漲靠前。中國聯通漲超6%；亞太衛星漲超4%；中國電信漲超2%。中國聯通跳空高開漲逾4%，公司發佈元宇宙戰略，打造一體化平臺。
綜合消費服務板塊走高。中國生命集團漲超37%；中國新華教育、卓越教育集團等多股漲超28%；嘉宏教育漲超24%；中國科培漲超17%。教育股繼續衝高，中國科培漲14.29%，機構指市場對高教行業的信心在逐步修復。
通信設備板塊全線走低。比亞迪電子跌超10%；摩比發展跌超9%；愛達利網絡、GBA集團等多股跌超7%；照現生態國際控股跌超5%。摩比發展12月22日回購4.2萬股。
互聯網醫療板塊多數下跌。阿裏健康、醫脈通等多股跌超4%；鷹瞳科技-B、平安好醫生等多股跌超2%。互聯網醫療獲政策支持，阿裏健康升逾4%。
居家用品板塊跌幅較前。維達國際跌超6%；凱富善集團控股、雷士國際等多股跌超4%；藍月亮集團跌超2%。
uSMART智能寫手的信息、數據均來自媒體公開報道，智能寫手不能保證其完全準確，內容僅供參考，不構成投資建議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
